Hagen Heidi
Hagen Heidi's purchase track record
Hagen Heidi has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/2/2021 | TCRT | $42K | -25.4% | -51.4% | -3.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Alaunos Therapeutics (TCRT) Moves in After-Hours Trading. Alaunos Therapeutics was listed among healthcare stocks moving in Friday's after-market session. The stock is currently trading near its support level of $1.97, with an RSI of 30.4 indicating it is in oversold territory. This price action occurs within a 52-week range of $0.97 to $4.59.
Transaction History
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 4/29/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 15,000 | $41K | 3/23/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 15,000 | $486K | 3/23/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 4/30/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 9,000 | $34K | 3/3/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 9,000 | $446K | 3/3/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 4,000 | $15K | 10/17/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 6,000 | $22K | 10/17/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 5/1/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,600 | — | 4/27/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,600 | — | 4/27/2022 | View on chart |
| TCRT | ▲ Buy | Open Market | 23,770 | $42K | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Truist lowers Vericel price target to $52
Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.
Truist lowers Vericel price target to $52. Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.